KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Deffered Revenue (2016 - 2020)

Nektar Therapeutics (NKTR) has 11 years of Non-Current Deffered Revenue data on record, last reported at $2.5 million in Q4 2020.

  • For Q4 2020, Non-Current Deffered Revenue fell 3.52% year-over-year to $2.5 million; the TTM value through Dec 2020 reached $2.5 million, down 3.52%, while the annual FY2020 figure was $2.5 million, 3.52% down from the prior year.
  • Non-Current Deffered Revenue reached $2.5 million in Q4 2020 per NKTR's latest filing, down from $2.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $60.1 million in Q2 2016 and bottomed at $2.5 million in Q4 2020.
  • Average Non-Current Deffered Revenue over 5 years is $24.5 million, with a median of $12.1 million recorded in 2018.
  • Peak YoY movement for Non-Current Deffered Revenue: decreased 1.51% in 2017, then plummeted 79.71% in 2018.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $51.9 million in 2016, then crashed by 63.34% to $19.0 million in 2017, then plummeted by 43.52% to $10.7 million in 2018, then tumbled by 76.23% to $2.6 million in 2019, then fell by 3.52% to $2.5 million in 2020.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $2.5 million in Q4 2020, $2.5 million in Q3 2020, and $2.5 million in Q2 2020.